Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Seena Magowitz Trial of CMP-001 and INCAGN01949 for Pancreatic and Other Cancers
NCT04387071Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of vidutolimod and INCAGN01949 in pancreatic adenocarcinoma (PDAC) and solid tumor (7 arms), sponsored by University of Southern California. Primary endpoints: Disease Control Rate at 2 months and Objective Response Rate at 2 months. Started Apr 2021; status: terminated.
02
Drugs
vidutolimodINCAGN01949
03
Conditions
pancreatic adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT04387071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387071.